NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has struck an agreement with Illumina to develop in vitro diagnostic kits for sequencing tests, the company said today.

Under the agreement, HTG will have the right to develop certain IVD test kits that use Illumina's sequencing technology.

HTG, based in Tucson, Ariz., has developed the HTG Edge platform, which uses the company's proprietary nuclease protection probe chemistry to prepare samples without the need to extract DNA or RNA.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.